Navigation Links
Intellectual Property Lawyer Available for Comment on Recent Supreme Court Ruling
Date:3/24/2012

BUFFALO, N.Y., March 23, 2012  /PRNewswire/ -- Jeremy P. Oczek, a registered patent attorney and Member in the Intellectual Property and Technology Group of Bond Schoeneck & King, is available to comment on the recent Supreme Court ruling that has significant implications for the medical and biotechnology industries.

In Mayo Collaborative Services v. Prometheus Labs, Inc., the Court unanimously ruled that a medicine dosing process that merely describes a "natural law" is not eligible for patent protection. Writing for the Court, Justice Stephen G. Breyer said Prometheus Laboratories' medical tests, designed to help doctors determine the most beneficial drug dosage by describing the correlation between metabolites in patients' blood and the likelihood that the dosage will be ineffective or harmful, were directed to laws of nature and therefore not eligible for patent protection. Justice Breyer cited Einstein's E=mc(2) formula and Newton's law of gravity as celebrated examples of natural laws that courts have long held are not patentable.

Mr. Oczek, a registered patent attorney in the Buffalo office of Bond, Schoeneck & King, PLLC, has litigated patent cases in federal courts throughout the United States. He has offered commentary on intellectual property issues for many national publications, including The National Law Journal, BNA's Patent, Trademark & Copyright Journal and Law360, and has published articles on intellectual property law in the Buffalo Law Journal, Sedona Conference Journal and Boston College Law Review.

Bond, Schoeneck & King, PLLC is a full-service law firm of more than 200 attorneys with offices in New York State, Kansas and Florida. For a complete list of practice areas and industries served, please visit www.bsk.com

To arrange a phone interview with Mr. Oczek, please contact Kim Parr, Director of Public Relations at Latorra, Paul & McCann at (315) 476-1646, ext. 225 or email kparr@lpm-adv.com

Links

Opinion by Justice Stephen G. Breyer:
http://www.supremecourt.gov/opinions/11pdf/10-1150.pdf

New York Times: Justices Back Mayo Clinic Argument on Patents:
http://www.nytimes.com/2012/03/21/business/justices-reject-patents-for-medical-tests-relying-on-drug-dosages.html?scp=1&sq=mayo%20v%20prometheus%20supreme%20court&st=cse

Wall Street Journal: Top Court's Patent Rejection Alarms the Biotech Industry:
http://online.wsj.com/article/SB10001424052702304724404577293390828369720.html?mod=WSJ_hp_LEFTWhatsNewsCollection

Jeremy P. Oczek:
http://www.bsk.com/attorneys/bio.cfm?ID=3009

Bond, Schoeneck & King:
http://www.bsk.com/

Contact:
Kim Parr
Latorra, Paul & McCann
(315) 476-1646, ext. 225
kparr@lpm-adv.com


'/>"/>
SOURCE Bond Schoeneck & King
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property
2. Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program
3. iPierian Expands Leadership Team With Experienced Business Development and Intellectual Property Executives
4. China YCT International Group, Inc. Announces That the State Intellectual Property Office of the Peoples Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd.
5. BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool
6. Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property
7. Finn, Warnke & Gayton Announces A New Service For Biotechnology Firms - A Platform To Sell Intellectual Property
8. Veteran Intellectual Property Team Joins Brown Rudnick
9. EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
10. Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
11. Hill-Rom Announces Sale of Negative Pressure Wound Therapy Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ProMIS ... precision treatments for neurodegenerative diseases, today announced it has issued a scientific white ... is one of a series of commentaries from ProMIS’s scientific team offering insight ...
(Date:2/22/2017)... 22, 2017 Origin (Origin Agritech, LLC, a subsidiary of ... provider, and Arcadia (Arcadia Biosciences, Inc., NASDAQ: ... commercializes agricultural productivity traits and nutritional products, today announced their collaboration ... developed in China to the ... ...
(Date:2/22/2017)... SAN DIEGO , Feb. 22, ... (OTCQB:CELZ) announced today expansion of its translational research ... product through establishment of laboratory facilities in San ... the San Diego BioLabs facility, a biotechnology incubator ... and Sanofi. In November 2016, the ...
(Date:2/21/2017)... ... February 21, 2017 , ... During HIMSS 2017, CloudMine, ... applications, announced a partnership with Redox, a leader in cloud-based healthcare integration and ... systems while keeping data secure in the cloud. , The digital health developers, ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, will present at the LEERINK Partners 6th ... Palace Hotel on Wednesday, February 15, 2017 at 10 ... of the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh ... the conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
Breaking Biology News(10 mins):